The share price was at $16.05 less than a year ago. Now X052 is a year closer to approval and now has orphan drug status.
I would expect it's reasonable to assume that the share price could hit $25.00 on a partnership with a company such as GSK, Takeda, or SNY.
$16.05 would be a nice start.
I just listened to the second quarter earnings call. It's obvious that finalizing a partnership is the key item on management's agenda. Discussions are ongoing.
Company is self-funded for the next year.
Share price was above $16.00 less tha a year ago and now the relevant time frames are a year closer to fruition.
This is definitely oversold.
They've been enticing us with a partnership for years. They are full of crap and have been stringing us along. We would not have had to have a R/S if Engle had a partner in the wings. This company is a fraud.